Search

Author/Creator Greasley, Peter J.

1. A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Issue 7 (25th March 2020)

Authors:
Mulder, Skander; Hammarstedt, Ann; Nagaraj, Sunil B.; Nair, Viji; Ju, Wenjun; Hedberg, Jonatan; Greasley, Peter J.; Eriksson, Jan W.; Oscarsson, Jan; Heerspink, Hiddo J. L.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 22:Issue 7(2020)
Page Start:
1157
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Issue 12 (9th September 2019)

Authors:
Yakovleva, Tatiana; Sokolov, Victor; Chu, Lulu; Tang, Weifeng; Greasley, Peter J.; Peilot Sjögren, Helena; Johansson, Susanne; Peskov, Kirill; Helmlinger, Gabriel; Boulton, David W.; Penland, Robert C.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 12(2019)
Page Start:
2684
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. (6th March 2020)

Authors:
Sokolov, Victor; Yakovleva, Tatiana; Chu, Lulu; Tang, Weifeng; Greasley, Peter J.; Johansson, Susanne; Peskov, Kirill; Helmlinger, Gabriel; Boulton, David W.; Penland, Robert C.
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 9:Number 4(2020)
Page Start:
222
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial. Issue 10 (20th August 2022)

Authors:
Squire, Iain B.; Gabrielsen, Anders; Greasley, Peter J.; Wernevik, Linda; Hartleib‐Geschwindner, Judith; Holden, Julie; Johansson, Susanne; Rudvik, Anna; Sánchez, José; Bamberg, Krister; Melin, Johanna; Whittaker, Andrew
Journal:
Clinical and translational science
Issue:
Volume 15:Issue 10(2022)
Page Start:
2493
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Issue 8 (1st June 2022)

Authors:
Sen, Taha; Scholtes, Rosalie; Greasley, Peter J.; Cherney, David Z. I.; Dekkers, Claire C. J.; Vervloet, Marc; Danser, Alexander H. J.; Barbour, Sean J.; Karlsson, Cecilia; Hammarstedt, Ann; Li, Qiang; Laverman, Gozewijn D.; Bjornstad, Petter; van Raalte, Daniel H.; Heerspink, Hiddo J. L.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 24:Issue 8(2022)
Page Start:
1578
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial. Issue 10 (October 2021)

Authors:
Edwards, Nicola C.; Price, Anna M.; Mehta, Samir; Hiemstra, Thomas F.; Kaur, Amreen; Greasley, Peter J.; Webb, David J.; Dhaun, Neeraj; MacIntyre, Iain M.; Farrah, Tariq; Melville, Vanessa; Herrey, Anna S.; Slinn, Gemma; Wale, Rebekah; Ives, Natalie; Wheeler, David C.; Wilkinson, Ian; Steeds, Ric...
Journal:
Clinical journal of the American Society of Nephrology
Issue:
Volume 16:Issue 10(2021)
Page Start:
1491
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Issue 12 (17th September 2019)

Authors:
Dekkers, Claire C. J.; Sjöström, C. David; Greasley, Peter J.; Cain, Valerie; Boulton, David W.; Heerspink, Hiddo J. L.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 12(2019)
Page Start:
2667
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. (August 2021)

Authors:
Fisk, Marie; Althage, Magnus; Moosmang, Sven; Greasley, Peter J.; Cope, Andrew P.; Jayne, David RW.; Galloway, James; Hall, Frances; Wilkinson, Ian B.; Ambery, Philip; Cheriyan, Joseph
Journal:
Pulmonary pharmacology & therapeutics
Issue:
Volume 69(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF. (22nd August 2022)

Authors:
Adamson, Carly; Cowan, Lorna M.; de Boer, Rudolf A.; Diez, Mirta; Drożdż, Jarosław; Dukát, Andre; Inzucchi, Silvio E.; Køber, Lars; Kosiborod, Mikhail N.; Ljungman, Charlotta E.A.; Martinez, Felipe A.; Ponikowski, Piotr; Sabatine, Marc S.; Lindholm, Daniel; Bengtsson, Olof; Boulton, David W.; Gre...
Journal:
European journal of heart failure
Issue:
Volume 24:Number 10(2022)
Page Start:
1856
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗